fell 2.4% to $28.20 after its second-quarter earnings declined from a year ago.
The company earned $1.19 million, or 74 cents a share, down from $1.43 million and 89 cents a share last year. Sales rose slightly.
, a company involved in the development of DNA vaccines, said its partner Tripep AB of Sweden received approvals from the Swedish Medical Products Agency and local ethics committees to initiate a phase I/II clinical trial of a novel DNA vaccine.
The vaccine is designed to treat chronically infected hepatitis C virus patients. Still, its shares dropped nearly 16% to $1.60.
, a biopharmaceutical research and development company, rose 3% to $2.32 on word that the Food and Drug Administration has granted the fast track designation for ANX-510, or CoFactor injection.
The product is currently being investigated in a phase III study, with 5-fluorouracil and bevacizumab, for the initial treatment of metastatic colorectal cancer.
Winthrop Realty Trust
was initiated with a hold rating at KeyBanc, but that was good enough for investors, who lifted the real estate investment trust 15.3% to $6.80.